Home

>

Newsroom

>

Press releases

Press releases

"Lupin Launches Suprax 400 mg Tablets in the US."

"Lupin expands its product basket in Japan"

"Lupin Q3 FY0708 Consolidated Net Profit up 192% to Rs. 1809 Mn"

"Lupin gets new Pharmaceutical Research Head"

"Lupin FY 2007-08 Q2 Consolidated Net Profit up 46% to Rs. 756 million"

"Lupin sells additional Perindopril patents to Servier"

"Lupin acquires in Japan"

"Lupin acquires pharmaceutical business of Rubamin"

"Lupin wins Ramipril product patent challenge at Federal Circuit "

"Lupin appoints Ramesh Swaminathan as President Finance & Planning "

"Lupin Receives “Best New Manufacturer of the Year” Award from AmerisourceBergen "

"Lupin FY 2007-08 Q1 Net Profit up 55% to Rs. 784 million"

"Lupin receives DCGI Approval to conduct Combined Phase IIb/III Clinical Trials for it’s herbal Psoriasis NCE"

"Lupin Receives US FDA Approval for Amlodipine"

"Lupin gets MHRA Approval for Lisinopril in UK"

"Lupin receives Final FDA Approval for Trandolapril"

"Lupin Receives US FDA Approval for Cefadroxil Capsules"

"Lupin and Symbiotec decide not to pursue their MoU "

"Lupin receives tentative US FDA Approval for Ziprasidone"

"Lupin Receives US FDA Approval for Simvastatin Tablets"

"DST and Lupin join hands over Migraine and Psoriasis "

"Lupin receives US FDA Approval for Novel Formulation of Suprax® Suspension "

"Lupin finalizes patent sale agreement with Servier "

"Lupin gets Marketing Approval for Cefpodoxime Proxetil in France "

"Lupin sells Intellectual Property on Perindopril to Servier "

"Lupin receives US FDA approval for Sertraline"

"Lupin and Aspen decide not to pursue their MOU"

"Lupin FY 2006-07 Q3 Net Profit up by 27% at Rs.560 mn"

"Lupin gets tentative US FDA approval for Sertraline"

"Lupin and Cornerstone End Development Agreement"

"Lupin's US Subsidiary and Chester Valley Pharmaceuticals decide to end promotion agreement"

"Lupin gets tentative US FDA approval for Trandolapril"

"Lupin gets DCGI approval to conduct Phase III clinical trials for Migraine NCE."

"Lupin FY 2006-07 Q2 Net Profit up by 29% at Rs.583 mn."

"Mr. Edward R. Roberts joins Lupin Board."

"Lupin and Dafra decide not to pursue their MoU."

"Lupin gets US FDA approval for Lisinopril-HCTZ Tablets."

"Lupin gets US FDA approval for Ceftriaxone 10gm vials."

"Lupin receives DCGI approval to conduct Phase II Clinical Trials for Psoriasis NCEs"

"Lupin FY 2006-07 Q1 Sales up by 33% at Rs.4.9 bn."

"Lupin gets USFDA approval for Meloxicam."

"Lupin announces District Court Ruling on Ramipril."

"Lupin Receives final approval for Quinapril Tablets."

"Rajan Dutta joins Lupin as President, HRD."

"Lupin to acquire 51% stake in Dafra."

"Lupin joins hands with ItalFarmaco to launch Lupenox in India."

"Lupin gets USFDA approval for Cefdinir Suspension."

"Lupin Announces Final FDA Approval of Cefdinir Capsules."

"Lupin's US Subsidiary Enters Into Collaboration to Promote AtopiclairT Nonsteroidal Cream to Pediatricians in the U.S."

Lupin-Aspen sign Joint Venture on 27 / 02 / 2006

Lupin LCTL Divestment 27 / 02 / 2006

Lupin to Reorganise Sale Structure for Suprax

Lupin Limited today announced that it plans to triple its spend on Research from Rs. 400 million in FY 2003-04 to Rs. 1.20 billion in FY 2004-05.
29 Jul 2004

  

Lupin and Ind-Swift launch new anti-diarrhoeal drug
9 Jun 2004

 

Lupin FY 2003-04 revenue up 22% at Rs 12.3 billion
28 Apr 2004

 

Lupin receives INDA approval for psoriasis oral treatment
22 Apr 2004

 

Lupin Launches Branded Finished Dosage in the US Sets up Pediatric Sales Force
06 Apr 2004

 

Lupin Enters into Collaboration to Promote Zymar to Pediatricians in the U.S.
29 Mar 2004

 

Lupin's non-cephalosporin oral finished dosage facility at Goa goes on stream
26 Mar 2004

 

Lupin unveils herbal products 
23 Mar 2004

 

Lupin Launches Herbal Business
22 Mar 2004

 

Lupin launches Herbal Business
22 Mar 2004

 

Lupin enters into an alliance with Baxter for Ceftriaxone
28 Feb 2004

 

Lupin receives USFDA approval for Cefixime Suspension
24 Feb 2004

 

Lupin receives USFDA approval for Cefixime Tablets
13 Feb 2004

 

Lupin Net Profit up 77% at Rs. 400 mn; Net Sales up 10% at Rs. 2629 mn;Debt Equity Ratio improves to 0.85:1
20 Jan 2004

 

Lupin appoints new President for Asia Pacific,Latin America
08 Jan 2004

 

Lupin launches novel cholesterol-fighter EZEDOC
02 Jan 2004

 

Lupin files INDA for anti-psoriasis
31 Dec 2003

 

Lupin receives IND approval for anti-migraine molecule
05 Dec 2003

 

Two Citigroup representatives join Lupin’s board
05 Dec 2003

 

Promoters sell 4% of Lupin equity
04 Nov 2003

 

Lupin promoters, Newbridge call off discussions
13 Oct 2003

 

Lupin promoters place 12.55% equity with CVC International
11 Oct 2003

 

Lupin Q2 FY 2003-04 net profit before extraordinary items at Rs.518 million,up 86%; sales up 36% at Rs 3609 million
10 Oct 2003

 

Lupin receives USFDA approval for ceftriaxone sterile vials for injection
01 Oct 2003

 

Lupin receives USFDA approval for cefotaxime sterile vials for injection
25 Sep 2003

 

Dr. Kamal K. Sharma to join Lupin as Managing Director
25 Aug 2003

 

Lupin Q1 FY 2003-04 net profit up 38% at Rs 280.6 million; sales up 23% at Rs 2,769 million
31 Jul 2003

 

Lupin receives USFDA approval for cefuroxime axetil tablets
28 Jul 2003

 

Lupin FY2002-03 net sales up 19% at Rs 10.3 billion
20 May 2003

 

Lupin launches once-a-day dosage cephalexin
09 May 2003

 

Statement on media reports linking SARS outbreak with demand for Lupin's ribavirin
17 Apr 2003

 

Lupin files ANDAs for Ceftriaxone and Cefotaxime
16 Apr 2003

 

Lupin to set up new Lovastatin plant A move to consolidate presence in lifestyle drugs
13 Feb 2003

 

Lupin Q3 sales up 19% at Rs. 2868 mn; net profit up 23% at Rs. 227mn
28 Jan 2003

 

Lupin Q2 sales up 23% at Rs. 2,985 mn; profit before tax up 35% at Rs. 353 mn
29 Oct 2002

 

Lupin Q1 FY03 sales at Rs 2514 million, up 8%; net up 26% at Rs 203 million
24 Jul 2002